Primary prevention
Immunoglobulin light chain (AL) amyloidosis is sporadic and no preventive interventions are recognized.
Development of secondary (AA) amyloidosis in a chronic inflammatory state is directly related to uncontrolled inflammation and hepatic production of serum amyloid A protein.[59] Treatment of the underlying condition to suppress the inflammation reduces the subsequent risk of AA amyloidosis.
Secondary prevention
Patients with multiple myeloma or monoclonal gammopathy of unknown significance (MGUS) should have regular clinical assessment. Repeat serum protein electrophoresis testing is indicated annually.
Routine screening for amyloidosis is not indicated unless the patient has increasing fatigue or edema, or if urinalysis shows proteinuria.
Use of this content is subject to our disclaimer